clearance – Page 7 – Communicable Diseases Research

Omicron variant Spike-specific antibody binding and Fc activity is preserved in recipients of mRNA or inactivated COVID-19 vaccines

Research Article

Published on 2022-03-152022-10-04
Journal: Science Translational Medicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단,

Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern

COVID-19 회복기의 면역 반응에 대한 종단적 추적은 우려의 다른 SARS-CoV-2 변종에 대한 오미크론 및 시차 손상에 대한 중화 활성의 부재를 나타냅니다

Article

Published on 2022-03-142022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 진단, 치료기술,

[키워드] activity Against Alpha alpha and delta variants analyzed antibodies association B cell B cells Beta cellular immunity cellular response Cellular responses changes in clearance Cohort concern Correlation analysis COVID-19 decrease Delta Delta variants Evaluating flow cytometry Gamma humoral humoral and cellular immunity humoral immune response IgG antibody IgG titer immune Immunity indicate indicated individual investigated lack long-lasting longitudinal memory memory B cell memory B cells neutralization capacity neutralization test Neutralizing antibodies neutralizing antibody omicron Omicron variants Other Patient patients persistence Perturbation phenotype Prospective Study protection Protective response SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 variant SARS-CoV-2 variants sera spike Spike-specific memory B cells surrogate virus neutralization test the disease variant variants variants of concern Viral virus neutralization test was measured Wuhan strain
[DOI] 10.3389/fimmu.2022.863039 PMC 바로가기 [Article Type] Article

SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity

특정 체액 면역이 없는 1차 항체 결핍 환자의 중증 및 치명적인 COVID-19에서 SARS-CoV-2 T 세포 반응

Article

Published on 2022-03-102022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술, 치료법,

[키워드] activated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Analysis analyzed antibody autoantibodies autoantibody Blood CD169 CD4 cellular characterized clearance clinical disease Comorbidities Comorbidity convalescent convalescent plasma Convalescent plasma (CP) coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 cytokine deficiency detectable elevated examined excluded expression fatal COVID-19 flow cytometry healthy individuals heterogeneous humoral humoral immune response IgG Immunity immunodeficiency immunological immunological mechanism Inborn errors indicate innate immune response Innate immunity interferon interferons lack marker median monoclonal antibody Monocytes morbidity Mortality mucosal naïve nucleocapsid outcome Patient patients peptide peptide pool Peripheral blood persistence phenotype primary antibody primary antibody deficiency (PAD) Primary immunodeficiencies primary immunodeficiencies (PID) producing Prophylactic respiratory response Risk factors robust SARS-CoV-2 SARS-CoV-2 immunity SARS-CoV-2 RNA SARS-CoV-2 spike SARS-CoV-2 viral shedding seronegative severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Severe case severe cases severe COVID-19 patient SIGLEC1 Specific T cell T cell response T cells Treatment type I interferon type I interferon response type I interferons undetectable Viral viral clearance viral shedding with COVID-19
[DOI] 10.3389/fimmu.2022.840126 PMC 바로가기 [Article Type] Article

Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

순환 중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 백신 항원 mRNA-1273 백신 수혜자의 혈장에서 검출

Article

Published on 2022-03-012022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 진단, 치료기술,

Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome

급성 COVID-19 증후군 환자의 전향적 코호트에서 장내 미생물 역학

Multicenter Study

Published on 2022-03-012022-09-11
Journal: Gut [Category] SARS, 유전자 메커니즘,

[키워드] Actinomyce Actinomyces Admission alteration analysed Bacteria Bacteroide Bifidobacterium Butyrate clearance Clostridium comparable Complication complications of COVID-19 conducted controls correlated COVID-19 COVID-19 severity defined Evidence evidence of facilitate Faecalibacterium fatigue Gut gut microbiome gut microbiome composition gut microbiota composition Hair loss intestinal INTESTINAL MICROBIOLOGY inverse correlation memory metagenomic sequencing Microbiome microbiota modulation Neuropsychiatric Non-COVID-19 nosocomial Occurrence Pathogens Patient persistent poor memory prospective cohort Prospective Study provided respiratory symptom SARS-CoV-2 virus shotgun Spectrum Symptom syndrome the SARS-CoV-2 virus viral clearance
[DOI] 10.1136/gutjnl-2021-325989 PMC 바로가기 [Article Type] Multicenter Study

Adipose tissue is a predictor of 30-days mortality in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Research Article

Published on 2022-02-212022-10-28
Journal: BMC Infectious Diseases [Category] Coronavirus, COVID19(2023년), Fulltext, MERS, SARS,

[키워드] 30-Day mortality 95% CI 95% confidence interval adipose Adipose tissue age all-cause mortality analyzed association Bacterial bloodstream bloodstream infection body composition BSI Carbapenem-resistant Klebsiella pneumoniae caused clearance complications COVID-19 Cox regression model effective eligible patient Factor hazard ratio high mortality hospital Infection investigated Klebsiella pneumoniae Mortality nomogram Patient patients performed physician Pneumonia poor prognosis previous study prognosis of patient Prognostic value Result SAT severity Skeletal muscle SOFA score statistical significance suffered suggested TAT tissue visceral
[DOI] 10.1186/s12879-022-07108-9 PMC 바로가기 [Article Type] Research Article

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

바이러스성 급성 호흡기 감염 치료를 위한 플라보노이드: 30건의 무작위 대조 시험에 대한 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2022-02-162022-09-11
Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 임상,

[키워드] achievement acute bronchitis acute respiratory tract infection adverse event adverse events Adverse reaction Adverse reactions alleviation alleviation of symptoms analyzed bronchial pneumonia bronchitis BSS changes in clearance common cold complementary and alternative medicine control group Controlled Controlled trial controlled trials COVID-19 duration of illness Efficacy analyses efficacy analysis Efficacy and safety eligible flavonoid flavonoids Hospitalization ICU Identifier incidence infections Influenza intensity limitations mechanical ventilation meta-analyses Meta-analysis Mortality not differ oxygen Patient patients hospitalized performed positive RCT RCTs respiratory respiratory tract infection Respiratory tract infections Result review rhinosinusitis RT-PCR Safe Safety severity sinusitis subject substantial risk suggested Symptom Symptoms systematic review TNF-α tonsillitis tonsillopharyngitis tract treating trials TSS Tumor tumor necrosis tumor necrosis factor tumor necrosis factor-α upper respiratory tract upper respiratory tract infections Viral
[DOI] 10.3389/fpubh.2022.814669 PMC 바로가기 [Article Type] Meta-Analysis

Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques

히말라야 원숭이에서 SARS-CoV-2 감염 후 면역 및 질병 매개변수에 대한 에어로졸 전달 BCG 백신의 영향

Immunology

Published on 2022-02-092022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 치료기술, 치료제,

[키워드] Activation acute respiratory syndrome adaptive aerosol Aerosol BCG vaccination antibody Antibody-mediated immunity antiviral immune response applied bacille Calmette-Guérin BAL BCG BCG vaccination Bronchoalveolar lavage cell-mediated immune response cellular challenge chemokine Classical CD14+ monocyte Classical CD14+ monocytes clearance collected comparable Concentration contribute coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 COVID-19 disease severity cross-protection cross-protective cross-reactive cytokine disease disease pathology disease severity early disease ENhance exceeded groups Heterologous High dose Histopathology Humoral immunity hypothesised immune cells immune mechanism immune response immune responses immune signature Immunity immunological parameters indicated induce Infection influence initial innate immune innate immune cell Innate immune cells Innate immunity Intervention intrabronchial intranasal macaque macaques marker mechanism Monocytes nasal nasal and pharyngeal swabs natural infection non-specific Occurrence parameter pharyngeal populations primary site priming quantified reduce respiratory respiratory pathogen rhesus macaque rhesus macaques SARS-CoV-2 secretion severe acute respiratory syndrome Coronavirus subsequent susceptible swabs T-cell T-cells the disease tissue tissue sample titre titres trained immunity Tuberculosis tuberculosis vaccine Vaccine Viral Viral RNA virus
[DOI] 10.3389/fimmu.2021.801799 PMC 바로가기 [Article Type] Immunology

Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection

중화 항체를 포함한 SARS-COV2 체액 반응의 발달은 치명적인 감염으로부터 환자를 보호하기에 충분하지 않습니다.

Clinical Trial

Published on 2022-02-082022-09-01
Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 유전자 메커니즘, 임상, 진단, 치료기술,

[키워드] animal models anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibodies antibody Antibody Response asymptomatic individual Asymptomatic individuals asymptomatic patients breath characterized clearance COVID-19 COVID-19 patients Deceased development died disease severity form health emergency house humoral Humoral response IgA IgM immune response Immunological disorders in viral in-house ELISA Infection management modulation Neutralization assay Neutralizing antibodies neutralizing antibody pandemic passive transfer Patient patients persistence plasma PROTECT question recovered patient recovered patients Region reported SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 serum severe COVID-19 specific antibodies the antibody response the disease the RBD titers titers of IgG transfer Vaccine design Viral viral clearance virus-specific antibodies while
[DOI] 10.1038/s41598-022-06038-5 PMC 바로가기 [Article Type] Clinical Trial

Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values

리툭시 맙 치료 후 연장 된 SARS-COV-2 감염 : 정량적 바이러스 배양 및 사이클 임계 값과 관련된 치료 중재에 대한 임상 과정 및 반응

Case Reports

Published on 2022-02-052022-09-01
Journal: Antimicrobial Resistance and Infection Control [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단, 치료기술,

[키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration antiviral therapies antiviral therapy approach B-cells clearance Clinical course Clinical parameters complex coronavirus correlated COVID-19 patient COVID-19 patients COVID-19 vaccination Cycle threshold value detection diagnostics highlight Immunocompromised patient Immunosuppressed Immunosuppression implication infection control Infection prevention maintenance nasopharyngeal swabs Oropharyngeal oropharyngeal or nasopharyngeal swabs parameters Patient PCR cycle Prevention and control Prolonged prolonged viral shedding Quantitative question raise recent respiratory reverse transcriptase risk factor RNA RT-PCR SARS-CoV-2 SARS-COV-2 infection Sequencing severe acute respiratory syndrome Coronavirus Steroids suggested supplementary material Therapeutic approach therapeutic intervention Therapeutics threshold vaccination Viral viral clearance viral culture viral shedding virus whole genome Whole genome sequencing
[DOI] 10.1186/s13756-022-01067-1 PMC 바로가기 [Article Type] Case Reports